Article
Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Hematology. American Society of Hematology. Education Program - 1 Jan 2009
Ottmann Oliver G, Pfeifer Heike
Abstract excerpt
The tyrosine kinase inhibitor (TKI) imatinib has become an integral part of front-line therapy for Ph(+) ALL, with remission rates exceeding 90% irrespective of whether imatinib is given alone or combined with chemotherapy. Treatment outcome with imatinib-based regimens has improved compared with historic controls, but most patients who do not undergo allogeneic stem cell transplantation (SCT) eventually relapse....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.